Company Profile

Amplistar (AKA: Elcatech Inc)
Profile last edited on: 5/1/2008      CAGE:       UEI:

Business Identifier: Post-genomics molecular diagnostics
Year Founded
1984
First Award
1986
Latest Award
1999
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

101 North Chestnut Street Suite 203
Winston-Salem, NC 27106
   (336) 777-3624
   klogan@amplistar.com
   www.amplistar.com
Location: Single
Congr. District: 05
County: Forsyth

Public Profile

Amplistar shut down operations in late 2002. Formerly known as Elcatech Inc, Amplistar, Inc. is a post-genomics company focused on the identification of a new category of molecular targets-antibody targets-for the early detection and treatment of cancer. A spin off from Wake Forest, Amplistar has developed proprietary technologies to rapidly identify these uniquely specific antibody targets that the Company believes will revolutionize the early detection of cancer. More specifically, the technology has the power of detecting early-stage disease for any type of cancer-making the market potential very significant. Amplistar's mission is to discover and commercialize a portfolio of highly-differentiated, value-added and patent-protected cancer testing products. These novel molecular targets can also be used for the development of therapeutic vaccines and therapeutic monoclonal antibodies, and the Company is working to enter into one or more collaborations to develop these drugs. Amplistar is on course to commence clinical trials of its first screening test (ovarian cancer) in early 2002, with a colon cancer screening test following over the next 12 months (other cancers are also being pursued). In addition, companies focusing on cancer therapies and vaccines have already approached the Company expressing interest in licensing the Company's proprietary cancer antibody targets

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1999 1 NIH $200,000
Project Title: Amplified immunoassay of bacteria and recovery
1998 1 NIH $100,000
Project Title: Autologous Antibodies In Ovarian Cancer
1998 1 NIH $100,000
Project Title: Amplified Card Immunoassay For Drugs In Saliva
1998 1 NIH $100,000
Project Title: System For Sensitive Detection Of Bacterial Pathogens
1996 2 NIH $799,534
Project Title: Novel ultrasensitive colorimetric assay for DNA

Key People / Management

  Eric Button -- President

  Allen G Beard

  George J Doellgast

  Sagypash T Sadiev

  Mark X Triscott

Company News

There are no news available.